keyword
MENU ▼
Read by QxMD icon Read
search

Her2 breast cancer

keyword
https://www.readbyqxmd.com/read/29667115/biopsy-feasibility-trial-for-breast-cancer-pathologic-complete-response-detection-after-neoadjuvant-chemotherapy-imaging-assessment-and-correlation-endpoints
#1
Gaiane M Rauch, Henry M Kuerer, Beatriz Adrada, Lumarie Santiago, Tanya Moseley, Rosalind P Candelaria, Elsa Arribas, Jia Sun, Jessica W T Leung, Savitri Krishnamurthy, Wei T Yang
PURPOSE: This study was designed to present the secondary imaging endpoints of the trial for evaluating mammogram (MMG), ultrasound (US) and image guided biopsy (IGBx) assessment of pathologic complete response (pCR) in breast cancer (BC) patients undergoing neoadjuvant chemotherapy (NAC). METHODS: Patients with T1-3, N0-3, M0 triple-negative or HER2-positive BC who received NAC were enrolled in an Institutional Review Board-approved prospective, clinical trial...
April 17, 2018: Annals of Surgical Oncology
https://www.readbyqxmd.com/read/29665100/accuracy-of-ultrasound-for-preoperative-assessment-of-tumor-size-in-patients-with-newly-diagnosed-breast-cancer-is-it-affected-by-the-background-parenchymal-echotexture
#2
Kyung Hee Ko, Eun Ju Son, In Wha Kim
OBJECTIVES: To assess the impact of the background parenchymal echotexture on the accuracy of tumor size estimation using breast ultrasound (US). METHODS: A total of 140 women with newly diagnosed invasive breast cancer from January 2014 to December 2015 were enrolled in this study. Two radiologists retrospectively reviewed US images in consensus for background parenchymal echotexture interpretation. The maximum tumor diameter from static images was recorded. Tumor size measurements were considered as having agreement with histologic results if they were within ±5 mm compared to the pathologic size...
April 17, 2018: Journal of Ultrasound in Medicine: Official Journal of the American Institute of Ultrasound in Medicine
https://www.readbyqxmd.com/read/29662653/plasma-thymidine-kinase-1-activity-predicts-outcome-in-patients-with-hormone-receptor-positive-and-her2-negative-metastatic-breast-cancer-treated-with-endocrine-therapy
#3
Martina Bonechi, Francesca Galardi, Chiara Biagioni, Francesca De Luca, Mattias Bergqvist, Magnus Neumüller, Cristina Guarducci, Giulia Boccalini, Stefano Gabellini, Ilenia Migliaccio, Angelo Di Leo, Marta Pestrin, Luca Malorni
The aim of this study was to investigate if thymidine kinase-1 (TK1), a well-known proliferation marker, could represent a valid circulating biomarker to identify hormone receptor positive (HR+)/HER2 negative (HER2neg) metastatic breast cancer (MBC) patients most likely to benefit from endocrine therapy (ET). We used the DiviTum™ assay to analyze TK1 activity in cell lysates of three HR+/HER2neg BC cell lines and in plasma of 31 HR+/HER2neg MBC patients receiving ET. Blood samples were collected at treatment initiation, after one month and at disease progression...
March 27, 2018: Oncotarget
https://www.readbyqxmd.com/read/29662649/-18-fdg-pet-ct-and-molecular-markers-to-predict-response-to-neoadjuvant-chemotherapy-and-outcome-in-her2-negative-advanced-luminal-breast-cancers-patients
#4
Patricia de Cremoux, Lucie Biard, Brigitte Poirot, Philippe Bertheau, Luis Teixeira, Jacqueline Lehmann-Che, Fatiha A Bouhidel, Pascal Merlet, Marc Espié, Matthieu Resche-Rigon, Christos Sotiriou, David Groheux
Background: The efficacy of neoadjuvant chemotherapy regimens in advanced luminal breast cancer patients is difficult to predict. Intrinsic properties of breast tumors, including altered gene expression profile and dynamic evaluation of metabolic properties of tumor cells using positron emission tomography/computed tomography (PET/CT) of tumor cells, have been identified to guide patient's prognosis. The aim of this study is to determine if both analyses may improve the prediction of response to neoadjuvant chemotherapy in ER-positive / HER2-negative breast cancers (BCs) patients...
March 27, 2018: Oncotarget
https://www.readbyqxmd.com/read/29661738/overexpression-of-lox-in-triple-negative-breast-cancer
#5
Cornelia Leo, Christine Cotic, Victoria Pomp, Daniel Fink, Zsuzsanna Varga
BACKGROUND: Triple negative breast cancer (TNBC) accounts for approximately 15% of breast cancers. It is associated with a poor prognosis and typically earlier onset of metastasis in comparison with other breast cancer subtypes. Since TNBC lacks the expression of estrogen and progesterone receptors and Her2 status is also negative, there is currently no target that can be used for systemic therapy. Epithelial-mesenchymal transition (EMT) plays an important role in tumor progression and metastasis...
March 27, 2018: Annals of Diagnostic Pathology
https://www.readbyqxmd.com/read/29661243/effect-of-neoadjuvant-chemotherapy-regimen-on-relapse-free-survival-among-patients-with-breast-cancer-achieving-a-pathologic-complete-response-an-early-step-in-the-de-escalation-of-neoadjuvant-chemotherapy
#6
Anna Weiss, Sami I Bashour, Kenneth Hess, Alastair M Thompson, Nuhad K Ibrahim
BACKGROUND: Patients with breast cancer who have a pathologic complete response (pCR) to neoadjuvant chemotherapy (NACT) have improved survival. We hypothesize that once pCR has been achieved, there is no difference in subsequent postsurgical recurrence-free survival (RFS), whichever NACT regimen is used. METHODS: Data from patients with breast cancer who achieved pCR after NACT between 1996 and 2011 were reviewed. RFS was estimated by the Kaplan-Meier method, and differences between groups were assessed using log-rank testing...
April 16, 2018: Breast Cancer Research: BCR
https://www.readbyqxmd.com/read/29661221/practice-patterns-and-outcomes-for-patients-with-node-negative-hormone-receptor-positive-breast-cancer-and-intermediate-21-gene-recurrence-scores
#7
Jonathan Chen, Xian Wu, Paul J Christos, Silvia Formenti, Himanshu Nagar
BACKGROUND: The recommendation for chemotherapy in early-stage breast cancer patients has been refined by the 21-gene Recurrence Score. However, uncertainty remains whether patients in the Intermediate Risk category benefit from chemotherapy. METHODS: We analyzed female patients from the National Cancer Database from 2006 to 2012 who had pT1c-T2N0M0 breast cancer, were ER/PR-positive and HER2-negative, received endocrine therapy, and had a 21-gene Recurrence Score from 11 to 25...
April 16, 2018: Breast Cancer Research: BCR
https://www.readbyqxmd.com/read/29660596/time-trends-of-overall-survival-among-metastatic-breast-cancer-patients-in-the-real-life-esme-cohort
#8
Elisa Gobbini, Monia Ezzalfani, Véronique Dieras, Thomas Bachelot, Etienne Brain, Marc Debled, William Jacot, Marie Ange Mouret-Reynier, Anthony Goncalves, Florence Dalenc, Anne Patsouris, Jean Marc Ferrero, Christelle Levy, Veronique Lorgis, Laurence Vanlemmens, Claudia Lefeuvre-Plesse, Simone Mathoulin-Pelissier, Thierry Petit, Lionel Uwer, Christelle Jouannaud, Marianne Leheurteur, Magali Lacroix-Triki, Audrey Lardy Cleaud, Mathieu Robain, Coralie Courtinard, Christian Cailliot, David Perol, Suzette Delaloge
AIM: Real-life analysis of overall survival (OS) trends among metastatic breast cancer (MBC) patients may help define medical needs and evaluate the impact of public health investments. The present study aimed to evaluate the independent impact of the year of MBC diagnosis on OS in the Epidemio-Strategy-Medical-Economical (ESME)-MBC cohort. METHODS: ESME-MBC (NCT03275311) is a French, national, multicentre, observational cohort including 16,702 consecutive newly diagnosed MBC patients (01 January 2008-31 December 2014)...
April 13, 2018: European Journal of Cancer
https://www.readbyqxmd.com/read/29659677/targeting-the-human-epidermal-growth-factor-receptor-2-her2-oncogene-in-colorectal-cancer
#9
S Siena, A Sartore-Bianchi, S Marsoni, H I Hurwitz, S J McCall, F Penault-Llorca, S Srock, A Bardelli, L Trusolino
BACKGROUND: Human epidermal growth factor receptor 2 (HER2) is an oncogenic driver, and a well-established therapeutic target in breast and gastric cancers. Using functional and genomic analyses of patient-derived xenografts, we previously showed that a subset (approximately 5%) of metastatic colorectal cancer (CRC) tumors are driven by amplification or mutation of HER2. MATERIALS AND METHODS: This paper reviews the role of HER2 as an oncogenic driver, a prognostic and predictive biomarker, and a clinically actionable target in CRC, considering the specifics of HER2 testing in this tumor type...
April 6, 2018: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/29657297/long-non-coding-rna-tug1-expression-is-associated-with-different-subtypes-in-human-breast-cancer
#10
Daniela F Gradia, Carolina Mathias, Rodrigo Coutinho, Iglenir J Cavalli, Enilze M S F Ribeiro, Jaqueline C de Oliveira
Taurine upregulated 1 gene ( TUG1 ) is a long non-coding RNA associated with several types of cancer. Recently, differential expression of TUG1 was found in cancerous breast tissues and associated with breast cancer malignancy features. Although this is evidence of a potential role in breast cancer, TUG1 expression could not be associated with different subtypes, possibly due to the small number of samples analyzed. Breast cancer is a heterogeneous disease and, based on molecular signatures, may be classified into different subtypes with prognostic implications...
December 20, 2017: Non-Coding RNA
https://www.readbyqxmd.com/read/29655990/inorganic-kernel-supported-asymmetric-hybrid-vesicles-for-targeting-delivery-of-stat3-decoy-oligonucleotides-to-overcome-anti-her2-therapeutic-resistance-of-bt474r
#11
Kai Shi, Yan Fang, Shan Gao, Dongjuan Yang, Hongshu Bi, Jianxiu Xue, Anqi Lu, Yuai Li, Liyuan Ke, Xiaojie Lin, Xuechao Jin, Min Li
As a recombinant humanized monoclonal antibody that targets the extracellular region of HER2 tyrosine kinase receptor, trastuzumab (TRAZ) has demonstrated comparable clinical efficacy and improved survival in patients with HER2-positive breast cancer. Nevertheless, the therapeutic potential of TRAZ is often limited due to its frequent resistance to anti-HER2 therapy. Therefore, we investigate the reversal effect of STAT3-specific decoy oligonucleotides (STAT3-decoy ODNs) on TRAZ resistance, which contain the consensus sequence within the targeted gene promoter of STAT3...
April 12, 2018: Journal of Controlled Release: Official Journal of the Controlled Release Society
https://www.readbyqxmd.com/read/29651385/clinicopathological-predictors-of-long-term-benefit-in-breast-cancer-treated-with-neoadjuvant-chemotherapy
#12
Marco Galvez, Carlos A Castaneda, Joselyn Sanchez, Miluska Castillo, Lia Pamela Rebaza, Gabriela Calderon, Miguel De La Cruz, Jose Manuel Cotrina, Julio Abugattas, Jorge Dunstan, Henry Guerra, Omar Mejia, Henry L Gomez
AIM: To investigate the survival impact of clinicopathological factors, including pathological complete response (pCR) and tumor-infiltrating lymphocytes (sTIL) levels according to subtypes, in breast cancer (BC) patients who received neo-adjuvant chemotherapy (NAC). METHODS: We evaluated 435 BC patients who presented and received NAC at the Instituto Nacional de Enfermedades Neoplasicas from 2003 to 2014. sTIL was analyzed as the proportion of tumor stroma occupied by lymphocytes, and was prospectively evaluated on hematoxylin and eosin-stained sections of the preNAC core biopsy...
April 10, 2018: World Journal of Clinical Oncology
https://www.readbyqxmd.com/read/29651273/are-there-differences-in-androgen-receptor-expression-in-invasive-breast-cancer-in-african-tanzanian-population-in-comparison-with-the-caucasian-italian-population
#13
Sara Bravaccini, Sara Ravaioli, Dino Amadori, Emanuela Scarpi, Maurizio Puccetti, Andrea Rocca, Maria Maddalena Tumedei, Nestory Masalu, Jackson Kahima, Akwilina Pangan, Lucas Faustine, Alberto Farolfi, Roberta Maltoni, Massimiliano Bonafè, Patrizia Serra, Giuseppe Bronte
Purpose: Androgen receptor (AR) has been shown to have prognostic implication on breast cancer (BC). Data on the biological features of African BCs are poor. We decided for the first time to compare AR expression of Tanzanian and Italian BC patients. Patients and methods: Of the 69 consecutive patients seen at the Bugando Medical Center (Mwanza, Tanzania) from 2003 to 2010, who underwent resection of primary BC evaluable for estrogen receptor, progesterone receptor (PgR), and HER2 only 65 were evaluable for AR by immunohistochemistry...
2018: Frontiers in Endocrinology
https://www.readbyqxmd.com/read/29650929/-a-case-of-her2-positive-occult-breast-cancer-presenting-as-swollen-axillary-lymphnodes
#14
Toshiyuki Ishiba, Goshi Oda, Tsuyoshi Nakagawa, Takumi Akashi, Yamato Yamashita, Tomoki Aburatani, Taichi Ogo, Yutaka Nakashima, Hironobu Baba, Naoaki Hoshino, Yoshinobu Nishioka, Tatsuyuki Kawano
Occult breast cancer, which develops as a metastatic lesion with no primary tumor detected in the breast, is a rare breast cancer. A 68-year-old female patient particularly complained of the presence of a right axillary mass. The mass in the right axilla was palpable, but no tumor was found in both the breasts on palpation, ultrasound examination, or MRI. Partial breast resection and axillary lymph node dissection were performed following a diagnosis of invasive ductal carcinoma by core needle biopsy. There was no mammary gland tissue present around the tumor due to the pathology of the disease, and the tumor was diagnosed as occult breast cancer...
March 2018: Gan to Kagaku Ryoho. Cancer & Chemotherapy
https://www.readbyqxmd.com/read/29650905/-a-case-of-her2-positive-breast-cancer-with-liver-metastases-showing-three-years-of-complete-response-to-combination-therapy-with-trastuzumabplus-pertuzumab
#15
Yuri Fujimoto, Kazushige Yamaguchi, Ayako Ueno, Reo Sakurai, Yoshio Nagahisa, Shiro Imai, Kazuyuki Kawamoto
A 48-year-old woman with severe interstitial pneumonitis was diagnosed with right breast cancer(invasive ductal carcinoma, T1aN1M0, ER+, PgR-, HER2 3+)and underwent modified radical mastectomy.The patient was administered tamoxifen as adjuvant therapy.However, 1 year after the mastectomy, multiple liver metastases were found and the patient received 2 anti-HER2 agents, trastuzumab and pertuzumab.A complete response(CR)was observed with the disappearance of the liver metastases in 7 months.CR was maintained for 2 years after the initiation of treatment, and then, we started trastuzumab monotherapy, which has resulted in long-term disease control...
March 2018: Gan to Kagaku Ryoho. Cancer & Chemotherapy
https://www.readbyqxmd.com/read/29650789/reparameterization-of-pam50-expression-identifies-novel-breast-tumor-dimensions-and-leads-to-discovery-of-a-genomewide-significant-breast-cancer-locus-at-12q15
#16
Michael J Madsen, Stacey Knight, Carol Sweeney, Rachel E Factor, Mohamed E Salama, Inge J Stijleman, Venkatesh Rajamanickam, Bryan E Welm, Sasi Arunachalam, Brandt Jones, Rakesh Rachamadugu, Kerry Rowe, Melissa Cessna, Alun Thomas, Lawrence H Kushi, Bette Caan, Philip S Bernard, Nicola J Camp
BACKGROUND: Breast tumor subtyping has failed to provide impact in susceptibility genetics. The PAM50 assay categorizes breast tumors into: Luminal A, Luminal B, HER2-enriched and Basal-like. However, tumors are often more complex than simple categorization can describe. The identification of heritable tumor characteristics has potential to decrease heterogeneity and increase power for gene-finding. METHODS: We used 911 sporadic breast tumors with PAM50 expression data to derive tumor dimensions using principal components (PC)...
April 12, 2018: Cancer Epidemiology, Biomarkers & Prevention
https://www.readbyqxmd.com/read/29644001/bag3-promotes-tumour-cell-proliferation-by-regulating-egfr-signal-transduction-pathways-in-triple-negative-breast-cancer
#17
Sarah Shields, Emer Conroy, Tony O'Grady, Alo McGoldrick, Kate Connor, Mark P Ward, Zivile Useckaite, Eugene Dempsey, Rebecca Reilly, Yue Fan, Anthony Chubb, David Gomez Matallanas, Elaine W Kay, Darran O'Connor, Amanda McCann, William M Gallagher, Judith A Coppinger
Triple-negative breast cancer (TNBC), is a heterogeneous disease characterised by absence of expression of the estrogen receptor (ER), progesterone receptor (PR) and lack of amplification of human epidermal growth factor receptor 2 (HER2). TNBC patients can exhibit poor prognosis and high recurrence stages despite early response to chemotherapy treatment. In this study, we identified a pro-survival signalling protein BCL2- associated athanogene 3 (BAG3) to be highly expressed in a subset of TNBC cell lines and tumour tissues...
March 20, 2018: Oncotarget
https://www.readbyqxmd.com/read/29643987/proteomic-analysis-defines-kinase-taxonomies-specific-for-subtypes-of-breast-cancer
#18
Kyla A L Collins, Timothy J Stuhlmiller, Jon S Zawistowski, Michael P East, Trang T Pham, Claire R Hall, Daniel R Goulet, Samantha M Bevill, Steven P Angus, Sara H Velarde, Noah Sciaky, Tudor I Oprea, Lee M Graves, Gary L Johnson, Shawn M Gomez
Multiplexed small molecule inhibitors covalently bound to Sepharose beads (MIBs) were used to capture functional kinases in luminal, HER2-enriched and triple negative (basal-like and claudin-low) breast cancer cell lines and tumors. Kinase MIB-binding profiles at baseline without perturbation proteomically distinguished the four breast cancer subtypes. Understudied kinases, whose disease associations and pharmacology are generally unexplored, were highly represented in MIB-binding taxonomies and are integrated into signaling subnetworks with kinases that have been previously well characterized in breast cancer...
March 20, 2018: Oncotarget
https://www.readbyqxmd.com/read/29628983/-fcrr3a-158-polymorphism-and-stromal-tumor-infiltrating-lymphocytes-and-survival-among-patients-with-metastatic-her2-positive-breast-cancer-receiving-trastuzumab-based-treatment
#19
Heejung Chae, Changhoon Yoo, Jung-A Yoon, Hee Jin Lee, Kyu-Pyo Kim, Jeong-Eun Kim, Jin-Hee Ahn, Kyung Hae Jung, Gyungyub Gong, Sung-Bae Kim
Purpose: The prognosis of human epidermal growth factor receptor 2 (HER2)-positive breast cancer has markedly improved since the introduction of trastuzumab. We aimed to evaluate the association between stromal tumor-infiltrating lymphocyte (sTIL) or FcrR polymorphisms and survival among patients with metastatic HER2-positive breast cancer who were treated with trastuzumab. Methods: A total of 56 women with recurrent or metastatic HER2-positive breast cancer who received the trastuzumab-taxane combination as first-line treatment were included in this retrospective analysis...
March 2018: Journal of Breast Cancer
https://www.readbyqxmd.com/read/29627705/3d-imaging-detection-of-her2-based-in-the-use-of-novel-affibody-quantum-dots-probes-and-ratiometric-analysis
#20
Perla Pérez-Treviño, Héctor Hernández-De la Cerda, Jorge Pérez-Treviño, Oscar Raúl Fajardo-Ramírez, Noemí García, Julio Altamirano
Patients with breast cancer (BC) overexpressing HER2 (HER2+) are selected for Trastuzumab treatment, which blocks HER2 and improves cancer prognosis. However, HER2+ diagnosis, by the gold standard, immunohistochemistry, could lead to errors, associated to: a) variability in sample manipulation (thin 2D sections), b) use of subjective algorithms, and c) heterogeneity of HER2 expression within the tissue. Therefore, we explored HER2 3D detection by multiplexed imaging of Affibody-Quantum Dots conjugates (Aff-QD), ratiometric analysis (RMAFI ) and thresholding, using BC multicellular tumor spheroids (BC-MTS) (~120 μm of diameter) as 3D model of BC...
April 4, 2018: Translational Oncology
keyword
keyword
5319
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"